Nicox and Soleus sign $16.5 million financing agreement

Nicox has entered into a $16.5 million financing agreement with Soleus Capital. The financing combines the sale of $15 million of VYZULTA royalties and an equity investment of $1.5 million in Nicox shares. The associated warrants potentially provide an additional $0.75 million in financing. This transaction will allow Nicox to repay €5.2 million of debt by June 2025, extending its financial horizon to the third quarter of 2025.

Nevertheless, Nicox continues its development in the ophthalmology sector. The results of the Denali phase 3 study on NCX 470 are expected for the third quarter of 2025. The launch of ZERVIATE in China is also expected, promising additional revenue sources. This collaboration with Soleus reinforces its growth strategy by attracting new specialized investors.